tert-butyl N-[1-(5-chloro-4-oxo-3-phenylquinazolin-2-yl)ethyl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: tert-butyl N-[1-(5-chloro-4-oxo-3-phenylquinazolin-2-yl)ethyl]carbamate
• 化学式: C₂₁H₂₂ClN₃O₃
• 分子量: 399.9
• InChiKey: PLVWGEXRALXJAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20140371246A1

  公开（公告）日：2014-12-18

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R 1 , R 2 , R 4 , and R 3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本公开提供了式（I）的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药用盐或异构体，其中n、m、R1、R2、R4和R3如本文所定义。这些化合物可用于治疗由一个或多个PI3K同工酶介导的疾病，如PI3Kδ。本公开还提供了包括式（I）的化合物、药用盐或异构体的药物组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K同工酶介导的疾病，如PI3Kδ的方法。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20150225410A1

  公开（公告）日：2015-08-13

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性（包括PI3激酶活性）的化合物和药物组合物，以及与激酶活性（包括PI3激酶活性）相关的疾病和病况的治疗方法、化合物和药物组合物。
• SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Calistoga LLC

  公开号：EP2941426B1

  公开（公告）日：2018-06-13
• ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Calistoga LLC

  公开号：EP2935246B1

  公开（公告）日：2018-07-25
• SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
  申请人：CALITOR SCIENCES, LLC

  公开号：US20160318913A1

  公开（公告）日：2016-11-03

  The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.